Monday, 2 December 2013

PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022. Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly’s blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool. These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

As in India, recession of the market for branded products will be caused by floods of generic products into the market. Like India, China will likely start issuing compulsory licenses for Chinese generics companies to violate IP rights and produce drugs prior to patent expiries. Therefore, The report expects the Chinese market to be dominated by generic products, and to lose significant value in the branded side of the drug market.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

To view the table of contents and know more details please visit PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis

Reportstack has announced a new market report on PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal. The Spanish influenza vaccine market is valued at approximately $33 million in 2012. The forecast drivers of growth include the launch of quadrivalent influenza vaccines and increase of the elderly population.

The market leader is trivalent Chiromas, Novartis’ adjuvanted influenza vaccine (marketed as Fluad in other countries). The adjuvant in this vaccine is designed to boost the immune response of elderly recipients, who often fail to be adequately protected by typical influenza vaccines. This improved immunogenicity has made Chiromas a popular selection among the elderly in Spain.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Spain seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in Spain.

To view the table of contents and know more details please visit PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis report. 

Similar Reports:

PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis

Reportstack has announced a new market report on PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, it projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. 

The US influenza vaccine market is valued at approximately $1.05 billion in 2012. The projected drivers for market growth include increased patient awareness on the importance of being vaccinated against influenza, the introduction of vaccines with a quadrivalent formulation, a growing elderly population, and introduction of vaccines with improved efficacy in elderly patients.

Sanofi is the current market leader. It was among the first influenza vaccines available in the US, and it has produced a diverse portfolio of influenza vaccines under Sanofi’s Fluzone brand. This brand includes trivalent vaccines with novel routes of administration (Fluzone ID) and vaccines with enhanced immunogenicity in elderly recipients (Fluzone High-Dose).

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US seasonal influenza market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in the US.

To view the table of contents and know more details please visit PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis report. 

Similar Reports:

Global and China Automotive Wiring Harness Industry Report, 2013

Reportstack has announced a new market research publication on Global and China Automotive Wiring Harness Industry Report, 2013. Global and China Automotive Wiring Harness Industry Report 2013 includes the following aspects:

1. The current situation of the global automotive market
2. The current situation of Chinese automotive market
3. Global and China automotive wiring harness industry
4. 18 major automotive wiring harness manufacturers

The global automotive wiring harness market value climb 2.3 percent to USD40.3 billion in 2013, and is expected to reach USD41 billion in 2014, up 1.6% over 2013. The slow growth is caused by many reasons. The market share of two major Japanese players of automotive wiring harness totals more than 50%, while Japanese Yen devaluates by 24% in 2013, resulting in a significant decline in the market value counted in the U.S. dollar. Also, due to the decline in copper prices as well as the continuous lawsuits against wiring harness price manipulating, manufacturers are forced to reduce prices to please customers.

After the United States fined several large automotive wiring harness companies who controlled prices, the European Union penalized four wiring harness suppliers (Yazaki, Yazaki’s European subsidiary SY System Tech, Leoni and Furukawa Electric) with EUR142 million in July 2013. Yazaki suffered the most penalty of EUR125 million, followed by SY System Tech who paid EUR11.05 million, Furukawa Electric EUR4 million and Leoni EUR1.3 million. Sumitomo Electric was exempted from penalty because it reported Cartel monopoly to the European Union.

In 2013, Furukawa Electric performs most actively in the investment in the field of automotive wiring harness. Furukawa Electric acquired Mitsubishi’s automotive connector business in late 2011 to increase investment in the field. In March 2013, the factory of Furukawa Electric in the Philippines was put into operation officially. In May 2013, Furukawa Electric decided to expand its Philippine factory whose Phase II is expected to be put into operation in January 2014. At the end of 2014, Furukawa Electric is expected to gain annual sales of JPY12 billion. Meanwhile, it established a new automotive wiring harness plant in Mexico, which started construction in May 2013 and will go into operation in January 2014. In September 2013, the Shenzhen subsidiary set up Wuhan Furukawa Automotive Systems Co., Ltd. in Wuhan, with an investment of RMB100 million.

In 2013, the most prominent change in the automotive wiring harness market lies in the poor performance of large manufacturers and the excellent performance of medium and small manufacturers. Top three players Yazaki, Sumitomo and Delphi offer high and inflexible prices. With the launch of a large number of high-quality automotive connectors, the technical threshold to automotive wiring harness is lowered. Due to the low output, small and medium-sized automotive manufacturers prefer small and medium-sized automotive wiring harness suppliers or self-production to control costs strictly. For example, the automotive wiring harness of Great Wall Motor is supplied by its subsidiary Baoding Mande Auto Parts Co., Ltd.; BYD’s supplier is its Fifteenth Division; Geely is supported by Geely Haoda Automotive Electrics.

To view the table of contents and know more details please visit Global and China Automotive Wiring Harness Industry Report, 2013.

PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. It expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

The report predicts that relative patient share for the three MenC conjugate vaccines will remain unchanged for the duration of the forecast period because Nuron Biotech’s Meningitec, Novartis’ Menjugate kit, and Baxter’s NeisVac-C possess nearly identical clinical profiles and price points. The MenC conjugate patient share is largely determined by prescriber preference in Spain and therefore is not expected to change drastically during the forecast period. In addition, It believes that an expected change in the booster administration age, from two to 11 years of age, will not dramatically alter sales, although a small coverage rate decrease associated with the older age group may occur (MSSSI, 2013).

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain

To view the table of contents and know more details please visit PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
 
The report expects the MenACWY patient share to remain stagnant because of the market’s high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. It anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIP’s current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK.

Scope

- Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US 

To view the table of contents and know more details please visit PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update

Reportstack has announced a new market report on PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

As in other regions, Italian physicians follow guidelines such as ACR, but also follow their own clinical experience. The process to diagnose a patient with RA in Italy usually begins with the PCP or GP regardless of which potential stage the patient is in, then progresses with the referral to a rheumatologist for further diagnosis and treatment. Also, most patients are between the ages of 35 and 55 and equally divided between male and females.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2011 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Italy rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in Italy
- Obtain sales forecast from 2011-2022 in the Italy.

To view the table of contents and know more details please visit PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update report. 

Similar Reports: